Lefamulin - Nabriva Therapeutics

Drug Profile

Lefamulin - Nabriva Therapeutics

Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabriva Therapeutics
  • Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bacterial infections; Bone and joint infections; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 30 Mar 2018 Nabriva Therapeutics completes phase I trial in Healthy volunteers in United Kingdom (NCT03131141)
  • 28 Mar 2018 Lefamulin licensed to Roivant Sciences in China, Hong Kong, Macau and Taiwan for the treatment of Community-acquired pneumonia
  • 16 Mar 2018 Nabriva Therapeutics announces intention to submit NDA to US FDA in Community-acquired pneumonia in second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top